Tsubota Laboratory Swings to Heavy Loss as Revenue Plunges, Forecasts Deep Full-Year Deficit

Tsubota Laboratory Incorporated ( (JP:4890) ) has shared an update.

Tsubota Laboratory reported a sharp deterioration in non-consolidated results for the nine months ended December 31, 2025, with revenue plunging 81.6% year on year to ¥145 million and swinging from a prior-year profit to a net loss of ¥520 million. Total assets fell to ¥1,672 million and equity declined to ¥1,105 million, though the equity ratio improved slightly to 66.1%, while the company maintained a zero-dividend policy and signaled a full-year forecast of continued heavy losses on sharply lower sales.

For the fiscal year ending March 31, 2026, the company projects revenue of ¥200 million, down 85.3% from the previous year, and expects an operating loss of ¥760 million and net loss of ¥740 million, indicating ongoing earnings pressure. With no revision to its existing forecasts and no planned dividend, the results highlight mounting profitability challenges and potential concerns for investors over the company’s ability to restore growth and stabilize its financial performance.

The most recent analyst rating on (JP:4890) stock is a Hold with a Yen303.00 price target. To see the full list of analyst forecasts on Tsubota Laboratory Incorporated stock, see the JP:4890 Stock Forecast page.

More about Tsubota Laboratory Incorporated

Tsubota Laboratory Incorporated is a Tokyo Stock Exchange-listed company focused on healthcare-related technologies, operating under Japanese GAAP. The company generates modest revenues and does not currently pay dividends, positioning itself as a growth-oriented player still investing in its development rather than returning capital to shareholders.

Average Trading Volume: 84,745

Technical Sentiment Signal: Sell

Current Market Cap: Yen7.25B

Find detailed analytics on 4890 stock on TipRanks’ Stock Analysis page.